Cytotoxicity and Biological Efficacy of Exendin-4-Encapsulated Solid Lipid Nanoparticles in INS-1 Cells

Figure 4

Insulinotropic activities of Eudragit exendin-4-encapsulated solid lipid nanoparticles in INS-1 cells. (a) Exendin-4 (Ex-4), Eudragit blank solid lipid nanoparticles (SLNs), and Eudragit Ex-4 SLNs were incubated for 24 h, and the insulin mRNA levels were examined using quantitative real-time polymerase chain reaction (qRT-PCR) analysis. Cyclophilin was used as an internal control. (b) Cells were treated as described above, and after 24 h, the cells were incubated in low (3 mM) or high (17 mM) concentration of glucose. The amount of insulin released into the supernatant was quantified using a rat insulin enzyme immunoassay (EIA) kit, and the level of insulin was normalized to the total amount of protein. Data were represented as mean ± standard error of mean (SEM; ), versus Eudragit blank SLNs, # < 0.05 versus 17 mM treated Eudragit blank SLNs.

(a)

(b)